ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises

C. Ponzetto, A. Guerrasio, C. Rosso, G. Avanzi, A. Tassinari, A. Zaccaria, F. LoCoco, R. Foa, G. Basso, M. L. Abate, P. M. Comoglio, G. Saglio

Research output: Contribution to journalArticlepeer-review

Abstract

The Philadelphia chromosome (Ph1) is present in 95% of chronic myelogenous leukaemias (CML) and 15% of acute lymphoblastic leukaemias (ALL). This cytogenetic marker is due to a t(9;22) translocation, which causes a rearrangement of the ABL oncogene. In order to better define the relationship between type of genomic rearrangement, variant ABL protein expressed and haematological phenotype, a series of Ph1-positive acute leukaemias, both myeloblastic (AML) and lymphoblastic, and several CML lymphoid blast crises have been analyzed at the DNA and protein level. The results confirm the presence of the ABL protein P210 in all cases of CML, ALL and AML positive for rearrangement in the bcr region of chromosome 22, and, surprisingly, in one AML case apparently negative for bcr rearrangement. The ABL protein P190 was found to be present only in cases of ALL negative for bcr rearrangement. Polymerase chain reaction (PCR) analysis of the types of 9/22 junctions present in the mRNA of CML lymphoid blast crises showed no evidence of 'ALL-type' transcripts.

Original languageEnglish
Pages (from-to)39-44
Number of pages6
JournalBritish Journal of Haematology
Volume76
Issue number1
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'ABL proteins in Philadelphia-positive acute leukaemias and chronic myelogenous leukaemia blast crises'. Together they form a unique fingerprint.

Cite this